RU2011148918A - Иммуноглобулин с двумя вариабельными доменами и его применение - Google Patents
Иммуноглобулин с двумя вариабельными доменами и его применение Download PDFInfo
- Publication number
- RU2011148918A RU2011148918A RU2011148918/10A RU2011148918A RU2011148918A RU 2011148918 A RU2011148918 A RU 2011148918A RU 2011148918/10 A RU2011148918/10 A RU 2011148918/10A RU 2011148918 A RU2011148918 A RU 2011148918A RU 2011148918 A RU2011148918 A RU 2011148918A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- fragment
- parent antibody
- specified
- test sample
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims 11
- 102000018358 immunoglobulin Human genes 0.000 title claims 11
- 239000000427 antigen Substances 0.000 claims abstract 225
- 102000036639 antigens Human genes 0.000 claims abstract 225
- 108091007433 antigens Proteins 0.000 claims abstract 225
- 230000027455 binding Effects 0.000 claims abstract 68
- 229920001184 polypeptide Polymers 0.000 claims abstract 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 51
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 50
- 108091008324 binding proteins Proteins 0.000 claims abstract 50
- 102000013519 Lipocalin-2 Human genes 0.000 claims abstract 43
- 108010051335 Lipocalin-2 Proteins 0.000 claims abstract 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 239000012634 fragment Substances 0.000 claims 129
- 238000000034 method Methods 0.000 claims 113
- 239000003795 chemical substances by application Substances 0.000 claims 76
- 238000011321 prophylaxis Methods 0.000 claims 36
- 230000001225 therapeutic effect Effects 0.000 claims 36
- 238000004458 analytical method Methods 0.000 claims 12
- 238000003745 diagnosis Methods 0.000 claims 12
- 238000012986 modification Methods 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 12
- 238000011156 evaluation Methods 0.000 claims 10
- 238000003018 immunoassay Methods 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 230000008827 biological function Effects 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17480009P | 2009-05-01 | 2009-05-01 | |
| US61/174,800 | 2009-05-01 | ||
| PCT/US2010/033246 WO2010127294A2 (en) | 2009-05-01 | 2010-04-30 | Dual variable domain immunoglobulins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011148918A true RU2011148918A (ru) | 2013-06-10 |
Family
ID=43032808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011148918/10A RU2011148918A (ru) | 2009-05-01 | 2010-04-30 | Иммуноглобулин с двумя вариабельными доменами и его применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110008766A1 (enExample) |
| EP (1) | EP2424566A4 (enExample) |
| JP (1) | JP2012525441A (enExample) |
| KR (1) | KR20140014382A (enExample) |
| CN (1) | CN102458459A (enExample) |
| AU (1) | AU2010242840B2 (enExample) |
| BR (1) | BRPI1012195A2 (enExample) |
| CA (1) | CA2760332A1 (enExample) |
| IL (1) | IL216048A0 (enExample) |
| MX (1) | MX2011011670A (enExample) |
| RU (1) | RU2011148918A (enExample) |
| SG (1) | SG175426A1 (enExample) |
| TW (1) | TW201116624A (enExample) |
| WO (1) | WO2010127294A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2758608C2 (ru) * | 2014-11-19 | 2021-11-01 | Конинклейке Филипс Н.В. | Способ диагностики с использованием hnl |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1392359E (pt) | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| WO2008091701A2 (en) * | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| CA2680854C (en) * | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| MX2010001757A (es) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| AU2009256246B2 (en) * | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| SG171812A1 (en) * | 2008-12-04 | 2011-07-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| TW201119673A (en) | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| UY32948A (es) | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| JP5918275B2 (ja) * | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
| JP2014509588A (ja) | 2011-03-01 | 2014-04-21 | アムジエン・インコーポレーテツド | 二特異性結合剤 |
| CA2857298A1 (en) | 2011-11-30 | 2013-06-06 | Abbvie Biotherapeutics Inc. | Vectors and host cells comprising a modified sv40 promoter for protein expression |
| WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| EP2893343B1 (en) | 2012-09-07 | 2019-11-20 | The Governors of the University of Alberta | Methods for diagnosis of inflammatory liver disease |
| HK1212359A1 (en) | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| GB201308271D0 (en) * | 2013-05-08 | 2013-06-12 | Nat Univ Ireland | Semi-automated whole blood immuno potency assay |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| MX375701B (es) | 2013-11-06 | 2025-03-06 | Astute Medical Inc | Ensayos para igfbp7 con mejor rendimiento en muestras biológicas. |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| ES2571441B1 (es) * | 2014-11-24 | 2017-03-07 | Instituto De Investigación Sanitaria - Fundación Jiménez Díaz | Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA) |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3684801A1 (en) * | 2017-09-22 | 2020-07-29 | H. Hoffnabb-La Roche Ag | Multivalent mono- or bispecific recombinant antibodies for analytic purpose |
| CN109678958B (zh) * | 2019-01-31 | 2022-03-18 | 重庆探生科技有限公司 | 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用 |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| US20240269285A1 (en) * | 2021-06-30 | 2024-08-15 | Board Of Regents, The University Of Texas System | Polypeptides targeting cd70-positive cancers |
| CN114366853B (zh) * | 2022-01-20 | 2023-04-14 | 华东理工大学 | 一种高诱骨活性牙种植体涂层及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| ES2091684T3 (es) * | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| BR0008758A (pt) * | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6818392B2 (en) * | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| CN1684708A (zh) * | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| NZ531818A (en) * | 2001-09-25 | 2005-10-28 | Fujisawa Pharmaceutical Co | Recombinant anti-osteopontin antibody and use in the treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis |
| RS53476B (sr) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| NZ545776A (en) * | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| WO2006047340A2 (en) * | 2004-10-22 | 2006-05-04 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| EP1860119B1 (en) * | 2005-02-28 | 2011-08-03 | Institute for Antibodies Co., Ltd. | ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME |
| ES2565481T3 (es) * | 2005-03-24 | 2016-04-05 | Thrombogenics N.V. | Anticuerpo anti-PlGF novedoso |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| TWI323734B (en) * | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2654000A1 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| ES2427924T3 (es) * | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | Biomarcador IGFBP2 |
| MY161894A (en) * | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2009003142A1 (en) * | 2007-06-27 | 2008-12-31 | The Board Of Trustees Of The Leland, Stanford Junior University | Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease |
| SG183709A1 (en) * | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
| WO2009021754A2 (en) * | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| CA2702590A1 (en) * | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| CN102227638B (zh) * | 2008-09-30 | 2015-05-20 | Abbvie公司 | Rna展示的改良方法 |
| MX2013004979A (es) * | 2010-11-02 | 2013-07-30 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| AR083705A1 (es) * | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2013102042A2 (en) * | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| US20130171059A1 (en) * | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| AU2012362370A1 (en) * | 2011-12-30 | 2014-07-24 | Abbvie Inc. | Dual variable domain immunoglobulins against receptors |
-
2010
- 2010-04-30 JP JP2012508795A patent/JP2012525441A/ja not_active Withdrawn
- 2010-04-30 KR KR1020117028863A patent/KR20140014382A/ko not_active Withdrawn
- 2010-04-30 CA CA2760332A patent/CA2760332A1/en not_active Abandoned
- 2010-04-30 CN CN2010800293591A patent/CN102458459A/zh active Pending
- 2010-04-30 US US12/771,874 patent/US20110008766A1/en not_active Abandoned
- 2010-04-30 EP EP10770449.6A patent/EP2424566A4/en not_active Withdrawn
- 2010-04-30 BR BRPI1012195A patent/BRPI1012195A2/pt not_active IP Right Cessation
- 2010-04-30 WO PCT/US2010/033246 patent/WO2010127294A2/en not_active Ceased
- 2010-04-30 RU RU2011148918/10A patent/RU2011148918A/ru not_active Application Discontinuation
- 2010-04-30 AU AU2010242840A patent/AU2010242840B2/en not_active Expired - Fee Related
- 2010-04-30 SG SG2011080231A patent/SG175426A1/en unknown
- 2010-04-30 TW TW099113910A patent/TW201116624A/zh unknown
- 2010-04-30 MX MX2011011670A patent/MX2011011670A/es not_active Application Discontinuation
-
2011
- 2011-10-30 IL IL216048A patent/IL216048A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2758608C2 (ru) * | 2014-11-19 | 2021-11-01 | Конинклейке Филипс Н.В. | Способ диагностики с использованием hnl |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011011670A (es) | 2011-11-18 |
| KR20140014382A (ko) | 2014-02-06 |
| WO2010127294A2 (en) | 2010-11-04 |
| AU2010242840B2 (en) | 2014-04-17 |
| BRPI1012195A2 (pt) | 2018-04-24 |
| EP2424566A2 (en) | 2012-03-07 |
| US20110008766A1 (en) | 2011-01-13 |
| CN102458459A (zh) | 2012-05-16 |
| TW201116624A (en) | 2011-05-16 |
| AU2010242840A1 (en) | 2011-12-15 |
| CA2760332A1 (en) | 2010-11-04 |
| JP2012525441A (ja) | 2012-10-22 |
| WO2010127294A3 (en) | 2011-01-20 |
| IL216048A0 (en) | 2012-01-31 |
| EP2424566A4 (en) | 2013-07-31 |
| SG175426A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011148918A (ru) | Иммуноглобулин с двумя вариабельными доменами и его применение | |
| RU2011148913A (ru) | Иммуноглобулин с двумя вариабельными доменами и его применение | |
| JP7346300B2 (ja) | 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法 | |
| JP2022115986A5 (enExample) | ||
| JP2021505844A (ja) | Ｇｆａｐとｕｃｈ−ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法 | |
| JP2021505843A (ja) | グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法 | |
| JP2020521951A (ja) | 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法 | |
| RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
| JP2020516603A5 (enExample) | ||
| US20240392034A1 (en) | Clinical assessment of m-protein response in multiple myeloma | |
| JP2023514952A (ja) | 抗ｄ－ダイマー組換え抗体、その方法及び使用 | |
| US20230236178A1 (en) | SPR-based dual-binding assay for the functional analysis of multispecific molecules | |
| CA3180569A1 (en) | Neutralizing antibody assay for therapeutic proteins | |
| US11505614B2 (en) | Antibodies binding to soluble BCMA | |
| RU2016106708A (ru) | Лекарственное средство, содержащее антитело к фосфолипазе d4 | |
| JP7416485B2 (ja) | スイッチング結合剤、その製造方法、及びそれを用いた薬学組成物、検査キット及び抗原と抗体との分析方法 | |
| KR102601835B1 (ko) | 말 인플루엔자 바이러스 h3n8형에 특이적인 단일클론항체 및 이를 이용한 말인플루엔자 바이러스 검출용 조성물 | |
| TWI741216B (zh) | 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途 | |
| JP5770092B2 (ja) | ヒトｈｉｇ１ポリペプチドに対するモノクローナル抗体 | |
| TW202216758A (zh) | 抗人類免疫缺陷病毒－１抗體、包含其的細胞、核酸、組合物及套組 | |
| WO2020264410A1 (en) | Troponin t binding agents and uses thereof | |
| CN114853887B (zh) | 一种特异性结合α-突触核蛋白的抗体及其应用 | |
| US20210278403A1 (en) | Lateral flow assay for assessing recombinant protein expression or reporter gene expression | |
| EP4194054A1 (en) | Camelid antibodies for use in therapy and diagnosis | |
| US20230242636A1 (en) | Monoclonal antibodies targeted to human taxilin alpha and methods for use of same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150202 |